Jeppson Wealth Management LLC Lowers Stake in Gilead Sciences, Inc. $GILD

Jeppson Wealth Management LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,497 shares of the biopharmaceutical company’s stock after selling 114 shares during the quarter. Jeppson Wealth Management LLC’s holdings in Gilead Sciences were worth $2,162,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the company. Beacon Investment Advisory Services Inc. raised its holdings in Gilead Sciences by 11.8% in the second quarter. Beacon Investment Advisory Services Inc. now owns 96,887 shares of the biopharmaceutical company’s stock valued at $10,742,000 after acquiring an additional 10,226 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Gilead Sciences by 4.1% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 598,346 shares of the biopharmaceutical company’s stock valued at $66,339,000 after acquiring an additional 23,641 shares during the last quarter. IMS Capital Management purchased a new stake in Gilead Sciences during the second quarter valued at about $225,000. Norden Group LLC lifted its position in shares of Gilead Sciences by 172.8% in the second quarter. Norden Group LLC now owns 73,771 shares of the biopharmaceutical company’s stock worth $8,179,000 after purchasing an additional 46,725 shares in the last quarter. Finally, Accurate Wealth Management LLC increased its holdings in Gilead Sciences by 33.8% in the second quarter. Accurate Wealth Management LLC now owns 6,305 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 1,591 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,390,030. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GILD. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Rothschild & Co Redburn increased their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Trading Down 0.6%

GILD opened at $113.67 on Thursday. Gilead Sciences, Inc. has a one year low of $81.83 and a one year high of $121.83. The business has a 50 day simple moving average of $114.29 and a two-hundred day simple moving average of $110.01. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $141.04 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences’s payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.